Disease · HP_0002653
Bone pain
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Bone pain. Diseases, record HP_0002653. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0002653
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Bone pain
- Open Targets ID
- HP_0002653
- Highest stage of its drugs
- Phase 3, for 2 of its 6 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs6
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| IBANDRONIC ACID | CHEMBL997 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ZOLEDRONIC ACID | CHEMBL4303669 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| LORATADINE | CHEMBL998 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PAMIDRONATE DISODIUM | CHEMBL3989401 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RESINIFERATOXIN | CHEMBL17976 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SAMARIUM SM 153 LEXIDRONAM PENTASODIUM | CHEMBL2096660 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets3
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| FDPS | Farnesyl pyrophosphate synthase | 3 | Farnesyl diphosphate synthase inhibitor | Phase 3 | https://conductscience.org/library/genes/2224 | Drugs and targets |
| HRH1 | Histamine H1 receptor | 1 | Histamine H1 receptor antagonist | Phase 2 | https://conductscience.org/library/genes/3269 | Drugs and targets |
| TRPV1 | Transient receptor potential cation channel subfamily V member 1 | 1 | Vanilloid receptor agonist | Phase 1/2 | https://conductscience.org/library/genes/7442 | Drugs and targets |
Trials6
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03883386 | Loratadine for Improvement of Bone Pain in Patients With Chronic Granulocyte-Colony Stimulating Factor (G-CSF) Use | Phase 2 | 3 | 2020-10-22 | Bone Pain | LORATADINE | Its record names the disease | ClinicalTrials.gov |
| NCT00082927 | Single-Dose Local Radiation Therapy Compared With Ibandronate in Treating Patients With Localized Metastatic Bone Pain | Phase 3 | 580 | Metastatic Cancer, Pain, Prostate Cancer | IBANDRONIC ACID | Its record names the disease | ClinicalTrials.gov | |
| NCT00482378 | Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain | Phase 1/2 | 39 | Multiple Myeloma and Plasma Cell Neoplasm, Pain | PAMIDRONATE DISODIUM, SAMARIUM SM 153 LEXIDRONAM PENTASODIUM, ZOLEDRONIC ACID | Its record names the disease | ClinicalTrials.gov | |
| NCT02522611 | Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain | Phase 1/2 | 30 | Intractable Pain, Palliative Care | RESINIFERATOXIN | Its record names the disease | ClinicalTrials.gov | |
| NCT02739555 | Zoledronic Acid Compared to Percutaneous Treatment in Osteoid Osteoma | Phase 3 | 15 | Osteoid Osteoma | ZOLEDRONIC ACID | Its record names the disease | ClinicalTrials.gov | |
| NCT00478270 | A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Metastatic Bone Disease. | Phase 2 | 0 | Pain, Bone Neoplasm, Neoplasm Metastasis | IBANDRONIC ACID | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials2
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Loratadine First vs Placebo First: deaths from any cause | 0 of 2 | 0 of 1 | 3 | NCT03883386 | Trial comparisons |
| Loratadine First vs Placebo First: serious adverse events | 0 of 2 | 0 of 1 | 3 | NCT03883386 | Trial comparisons |
Papers from its trials0
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
None in this release.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0002653
GET https://conductscience.org/api/diseases/v1/HP_0002653/drugs